VYNE Therapeutics files presentation regarding proposed reverse merger.
VYNE Therapeutics filed Exhibit 99.1 detailing a proposed reverse merger with Yarrow Bioscience and concurrent financing. This corporate restructuring could provide VYNE's preclinical programs with necessary capital and strategic oversight.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day